IL17A and systemic lupus erythematosus: The RhoA/ROCK inhibitor, Y27632, also attenuates disease development in lupus-prone mice by diminishing T cell production of IL-17 and IL-21 (36), and it reduced serum concentrations of tumor necrosis factor-α (TNF-α), IL-1β and interleukin-6 (IL-6) while increasing levels of of IL-10 (37).